search

Oric Pharmaceuticals Inc (ORIC)

OverviewChartFinancialsStatisticsEarningsInsider transactionsETFsNews

News

Real-time news feed aggregating press releases, regulatory filings, and global media coverage for a single company, filterable by date range, relevance score, and sentiment classification. Each article is tagged with company-specific and overall market sentiment — allowing investors to separate fundamental catalysts from broader market noise and monitor how the narrative around a stock is evolving over time.

Relevance *
40
1,078,055 Shares of Oric Pharmaceuticals, Inc. $ORIC Purchased by Bank of America Corp DE
Sep 26, 2026

1,078,055 Shares of Oric Pharmaceuticals, Inc. $ORIC Purchased by Bank of America Corp DE

Bank of America Corp DE recently acquired 1,078,055 shares of Oric Pharmaceuticals (NASDAQ:ORIC), valued at approximately $11.7 million, representing about 1.04% of the company. Institutional investors now own 95.05% of ORIC, and analysts maintain a "Moderate Buy" consensus with an average price target of $20.18. The company recently reported a quarterly loss of $0.38 per share, missing estimates, and its CFO sold 77,000 shares under a pre-arranged trading plan.
Company relevance
100.00%
Company sentiment
Neutral
Overall sentiment
Neutral
Oric Pharmaceuticals (NASDAQ:ORIC) Shares Gap Up - Still a Buy?
Sep 23, 2026

Oric Pharmaceuticals (NASDAQ:ORIC) Shares Gap Up - Still a Buy?

Oric Pharmaceuticals (NASDAQ:ORIC) shares gapped up before market open but traded down to $13.3950. The company, a clinical-stage cancer biopharmaceutical firm, reported a quarterly loss of $0.38 per share and has a "Moderate Buy" consensus rating from analysts with an average price target of $20.18. Despite a CFO selling over 77,000 shares, institutional investors own 95.05% of the stock.
Company relevance
100.00%
Company sentiment
Somewhat-Bullish
Overall sentiment
Somewhat-Bullish